U.S. flag

An official website of the United States government

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

  • This publication is provided for historical reference only and the information may be out of date.

This publication is provided for historical reference only and the information may be out of date.

Cover of Drug Class Review: Atypical Antipsychotic Drugs

Drug Class Review: Atypical Antipsychotic Drugs

Final Report Update 2

, PharmD, , MS, , MPH, , MS, and , MPA:HA.

Author Information and Affiliations
Portland, (OR): Oregon Health & Science University; .

"Atypical" antipsychotic agents are used to treat the symptoms of schizophrenia and bipolar disorder. The atypical antipsychotics interact with more neurotransmitter receptor types than conventional antipsychotics and vary from one another in receptor interaction selection and affinity. In general, atypical antipsychotics produce antipsychotic responses with fewer acute extrapyramidal side effects than "conventional" antipsychotic drugs. This review addresses the use of atypical antipsychotics to treat schizophrenia, bipolar disorder, behavioral and psychological symptoms of dementia (BPSD) in adults, and pervasive developmental disorders and disruptive behavior disorders in children. The purpose of this review is to help policy makers and clinicians make informed choices about the use of atypical antipsychotics by evaluating their comparative effectiveness and harms.

Contents

The funding source, the Center for Evidence-based Policy, is supported by 14 organizations, including 13 state Medicaid programs. These organizations selected the topic and had input into the Key Questions for this review. The content and conclusions of the review are entirely determined by the Evidence-based Practice Center researchers. The authors of this report have no financial interest in any company that makes or distributes the products reviewed in this report.

Suggested citation:

McDonagh MS, Peterson K, Carson S, Chan B, Thakurta S. Drug class review on atypical antipsychotic drugs. Update #2 final report. http://www.ohsu.edu/drugeffectiveness/reports/final.cfm

The purpose of this report is to make available information regarding the comparative effectiveness and safety profiles of different drugs within pharmaceutical classes. Reports are not usage guidelines, nor should they be read as an endorsement of, or recommendation for, any particular drug, use or approach. Oregon Health & Science University does not recommend or endorse any guideline or recommendation developed by users of these reports.

Copyright © 2008, Oregon Health & Science University, Portland, Oregon.
Bookshelf ID: NBK10401PMID: 20495725

Views

Other titles in this collection

Similar articles in PubMed

See reviews...See all...

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...